FibroScan Limitations: What Australian Clinics Need to Know | Elastography Australia

FibroScan (Echosens) defined the liver elastography market and remains widely used in Australian hospitals and specialist centres. For many clinicians, it was the first transient elastography system they trained on.

But as the market has matured and guided alternatives have emerged, the limitations of blind vibration-controlled transient elastography (VCTE) are increasingly documented in the peer-reviewed literature. This article summarises what the evidence shows — and what it means for Australian practices evaluating their options.

Limitation 1: High Failure and Unreliable Result Rates in Obese Patients

The most clinically significant limitation of standard FibroScan is acquisition performance in higher-BMI patients. Published studies consistently report M-probe failure rates of 5–16% in general cohorts, rising to 20–25% in patients with BMI over 30.

Even with the XL probe — designed for obese patients — unreliable result rates (IQR/median >30%) remain elevated compared to guided systems. A 2020 meta-analysis in the Journal of Hepatology found that BMI >30 independently predicted failed or unreliable transient elastography acquisitions.

In Australian clinical practice, where a large proportion of MAFLD patients are overweight or obese, this is not a marginal issue. A practice running 15 scans per week with a 20% failure rate in its obese cohort is absorbing significant wasted appointment time and foregone revenue.

Limitation 2: Blind Measurement — No Visual Confirmation of Probe Position

Standard FibroScan acquisition is performed without live B-mode ultrasound guidance. The operator positions the probe using anatomical landmarks and palpation, then fires the acquisition without seeing where in the liver parenchyma the shear wave is propagating.

This blind approach creates two problems. First, incorrect probe placement — over an intercostal space, a rib shadow, or a large intrahepatic vessel — can produce measurements that do not represent true liver stiffness. Second, operator skill variance is higher: a trained sonographer and an upskilling nurse practitioner will not achieve equivalent results with a blind system, whereas live imaging guidance narrows that gap substantially.

The practical consequence in busy clinics is that results quality is dependent on individual operator consistency, which is difficult to maintain in settings with staff rotation or high patient throughput.

Limitation 3: Workflow Speed and Throughput

FibroScan acquisition typically requires 10 valid measurements with IQR/median ≤30% for a reliable result. In straightforward patients, this takes approximately 5–7 minutes. In challenging body habitus or technically difficult patients, it can take significantly longer — or end in an unreliable or failed result after multiple attempts.

Guided elastography systems that allow the operator to visualise liver depth and position in real time achieve median exam times of approximately 2 minutes in published cohort data. For imaging centres billing by throughput, this difference directly affects how many patients can be scanned per session.

Limitation 4: Probe Strategy and Cost

A complete FibroScan setup for an Australian mixed-BMI patient population requires both the M probe (standard patients) and the XL probe (obese patients). Each probe is an additional capital cost, and managing probe selection in a busy clinic adds a step to the workflow.

Systems using a single universal probe — covering the full BMI range without probe switching — reduce capital outlay and simplify the operator workflow. For practices setting up a new elastography service, the all-in device cost is a meaningful variable in the payback period calculation.

Limitation 5: No Concurrent B-Mode Imaging

FibroScan does not produce a B-mode ultrasound image alongside the stiffness measurement. This means the operator cannot simultaneously assess for gross morphological changes, large lesions, or obvious cirrhotic features during the elastography acquisition.

Guided systems that integrate B-mode imaging provide the operator with a basic visual reference during the scan. While this does not replace a full diagnostic ultrasound examination, it adds clinical context and supports safer probe positioning.

What This Means for Procurement Decisions

FibroScan remains a validated, guideline-referenced tool, and the clinical evidence base behind transient elastography as a method is robust. The limitations above are practical and operational rather than a challenge to the underlying measurement principle.

For practices evaluating their first elastography purchase, or practices replacing an ageing FibroScan unit, the relevant questions are: what is your patient BMI profile, how many scans per week do you expect to run, how experienced are your operators, and what is the total device cost including probes?

If your patient population skews toward higher BMI — as is common in MAFLD, T2DM, and metabolic syndrome cohorts — the failure rate differential between blind and guided systems has direct revenue and pathway implications.